Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 HUF: hydroxychloroquine combinations in hospitalized SARS-CoV-2 pneumonia
2020-001321-31Phase 2Completed
- Sponsor
- Hospital Universitario de Fuenlabrada
- Start
- Apr 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and viral pneumonia comparing Hydroxychloroquine + baricitinib, Hydroxychloroquine + imatinib and Hydroxychloroquine + lopinavir + ritonavir (3 arms). Primary endpoints: Time to clinical improvement and Demographics. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-001321-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001321-31.